NCI Scientists Find Specific Mutation in the Breast Cancer Gene

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

BETHESDA, Md-Scientists from the National Cancer Institute have found a specific mutation, 185delAG, in the breast cancer 1 gene (BRCA1) in almost 1% of DNA samples from a study group of Eastern European (Ashkenazi) Jews. This is the first time that scientists have been able to show that the gene mutation is present at measurable levels not only in high-risk families but also in a specific group of the general population.

BETHESDA, Md-Scientists from the National Cancer Institute havefound a specific mutation, 185delAG, in the breast cancer 1 gene(BRCA1) in almost 1% of DNA samples from a study group of EasternEuropean (Ashkenazi) Jews. This is the first time that scientistshave been able to show that the gene mutation is present at measurablelevels not only in high-risk families but also in a specific groupof the general population.

At a press conference, Donna Shalala, secretary of the US Departmentof Health and Human Services, said that "this exciting findingshould allow us to move rapidly toward our goal of identifyinghigh-risk women and helping them to prevent breast cancer beforeit strikes."

The study, an international collaboration between the NationalCenter for Human Genome Research (NCHGR), the NCI, the SarettInstitute (Jerusalem), and the University of California, San Diego,involved 858 unrelated Ashkenazi Jews from the United States andIsrael whose family or personal cancer histories were not known.

Eight (1%) of the individuals tested were found to have the 185delAGmutation. This rate of alteration in the BRCA1 gene is three timeshigher than all BRCA1 alterations combined in the general population.Scientists did not find the alteration in 815 other samples fromindividuals not selected for ethnic origins.

Dr. Jeffery Struewing, lead author of the report (Nature Genetics,October, 1995), cautioned that the results were too preliminaryto recommend immediate BRCA1 testing for the nation's 5.5 millionAshkenazi Jews. However, NIH has announced plans to launch a seriesof clinical studies to evaluate cancer risk in Ashkenazi Jewsbearing the mutation.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.